

LIVERACE™ SINGLEPLEX · PRODUCT OVERVIEW

Unlocking the Power of PCR-Free miRNA Biomarkers.

miRNA-122 detection from as little as 25 µL. Earlier, more liver-specific, and cross-species compatible. The precision your drug safety programme demands.



LiverAce™ SinglePlex

ACCURATE PCR-FREE
MIRNA-122 DETECTION

Luminex Ready

Cross-Species

25 µL Sample

- **Earlier than ALT/AST. Liver-specific.** miR-122 peaks hours before standard liver enzymes with no false positives from muscle injury or other pathologies, enabling fail-fast decisions in preclinical and clinical safety studies.
- **isomiR-level specificity.** Destina Chemistry overcomes the isomiR degradation problem that defeats PCR, delivering single-nucleotide resolution without amplification.
- **FDA Letter of Support.** miR-122 qualified via the IMI TransBioLine Consortium. The only commercial PCR-free single-well assay aligned with these regulatory scientific findings.

FOR RESEARCH USE ONLY · NOT FOR DIAGNOSTIC PROCEDURES

www.destinagenomics.com · info@destinagenomics.com

Av. de la Innovación 1, Office 112 · 18016 Granada, Spain

© 2026 Destina Genómica S.L.



LEARN MORE

PRODUCT

For Pharma & CROs

LiverAce™ SinglePlex

Accurate PCR-free miRNA-122 detection

miRNA-122 is a well-established early biomarker for liver toxicity, validated from organoids across small and large animal species to humans, rising much earlier and more liver-specific than AST/ALT.

By overcoming the isomiR degradation challenge that defeats PCR, LiverAce™ SinglePlex delivers the "Fail-Fast" precision required for confident drug development decisions.



miRNA detection using **immunoassay workflows** and platforms

The Challenge of Liver Toxicity in Drug Development.

! Testing Limitations (ALT / AST)

Traditional indicators lack specificity and are released by non-hepatic tissues, leading to false safety flags that incorrectly kill viable drug candidates.

✓ PCR's Fatal Flaw: isomiRs

PCR cannot distinguish miRNA variants (isomiRs): degradation products that create false negatives. This renders PCR unreliable for clinical miRNA diagnostics.

\$ Billions

LOST OPPORTUNITIES FROM FALSE POSITIVE SIGNALS AND LATE-STAGE FAILURES DUE TO HEPATOTOXICITY

#1

DILI IS THE LEADING CAUSE OF ACUTE LIVER FAILURE WORLDWIDE

KEY FEATURES



Early Detection

miR-122 peaks hours ahead of ALT/AST



isomiR Specificity

PCR-Free single-nucleotide resolution



Liver-Specific

No false positives from muscle injury or other pathologies



25 µL Sample

For small animal models (mouse/rat) where blood volume is scarce



Luminex Ready


No capital investment needed



Cross-Species

Preclinical → Clinical

BIOMARKER DETECTION



REGULATORY VALIDATION

- ✓ FDA Letter of Support for miR-122 — IMI TransBioLine Consortium research
- ✓ Only commercial single-well PCR-free miR-122 assay matching consortium scientific findings

COMPLETE DRUG DEVELOPMENT PROCESS — ONE ASSAY

